Bozitinib, also known as vebreltinib, is an orally bioavailable small-molecule inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor). It selectively binds to c-Met, disrupting its signal transduction pathways and inducing cell death in tumor cells that overexpress or have constitutively activated c-Met.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Bozitinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Capmatinib dihydrochloride monohydrate
pharmaceutical raw material
Ledipasvir acetone
pharmaceutical raw material
Ripretinib
pharmaceutical raw material
2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-7-oxido-9H-purin-9-yl]-, (1S,4R)-
pharmaceutical raw material
Landiolol hydrochloride
pharmaceutical raw material
The international HS code for Bozitinib (CAS 1440964-89-5) is 2933.19.
2933.19
2933 19 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
QHXLXUIZUCJRKV-UHFFFAOYSA-N
CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
Sourcing Bozitinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.